ArticleThoracic cancer2019
Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 97 citations in OpenAlex.
- A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort.Cancer communications (London, England) · 2025Trial
- Clinicopathological characteristics and therapeutic outcomes in patients with non-small cell lung cancer harboringAnnals of medicine · 2026Article
- A thoracic SMARCA4-deficient undifferentiated tumor: A case report.Oncology letters · 2026Article
- SMARCA4-Deficient Carcinomas of the Small Intestine: A Systematic Review.Current oncology (Toronto, Ont.) · 2026Review
- Small intestinal SMARCA4-deficient undifferentiated carcinoma with intussusception: A case report.Oncology letters · 2026Article
- Case Report: SMARCA4-deficient non-small cell lung cancer - effective local control with radiotherapy and emergence of a targetable EGFR mutation.Frontiers in oncology · 2026Article
- Clinical characteristics and prognostic analysis of 22 cases of SMARCA4-deficient thoracic tumors: a retrospective observational study.Journal of thoracic disease · 2025Article
- Successful treatment with sintilimab plus anlotinib for SMARCA4-deficient non-small cell lung cancer withMET exon 14 skipping: a case report.Nagoya journal of medical science · 2025Article
- A case report on SMARCA4 deficient cervical adenocarcinoma with high-grade squamous intraepithelial lesion.World journal of surgical oncology · 2025Article
- The role of SMARCA4 in lung cancer.Scientific reports · 2025Review
- Successful treatment with sintilimab for SMARCA4-deficient non-small cell lung carcinoma: two case reports.Discover oncology · 2025Article
- Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review.World journal of surgical oncology · 2025Review
- In silico evaluation of the immunogenic profile of lung cancers with SMARCA4 genetic alterations.Scientific reports · 2025Article
- Article
- Article
- When rarity meets thoracic cancers: a narrative review from ITMIG 2024.Mediastinum (Hong Kong, China) · 2025Review
- SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review.Frontiers in immunology · 2025Review
- A retrospective study of the efficacy and safety of immune checkpoint inhibitors combined with chemotherapy for the treatment of SMARCA4-deficient thoracic tumors.Translational lung cancer research · 2024Article
- SMARCA4 mutations and expression in lung adenocarcinoma: prognostic significance and impact on the immunotherapy response.FEBS open bio · 2024Article
- SMARCA4-Deficient Undifferentiated Esophageal Carcinoma: A Clinical Case Series and Literature Review.Journal of gastrointestinal cancer · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SMARCA4 is a subunit of the switch/sucrose non-fermentable (SWI/SNF) chromatin-remodeling complex. An effective treatment for SMARCA4-deficient non-small cell lung carcinoma (NSCLC) has not yet been established. Correlations between a response to immune checkpoint inhibitors and the SWI/SNF complex have been suggested, but little is known about the efficacy of immune checkpoint inhibitors against SMARCA4-deficient NSCLC. A 43-year-old man underwent left upper lobe lung resection and was diagnosed with SMARCA4-deficient lung adenocarcinoma. Two months after surgery, multiple lung metastases appeared. Immunohistochemical analysis showed no PD-L1 expression. Whole-exon sequencing revealed a relatively high tumor mutation burden at 396. After the failure of three standard chemotherapy regimens, the patient was treated with nivolumab as fourth-line treatment. An obvious reduction in the lung metastases was obtained for more than 14 months. We report the first case of SMARCA4-deficient NSCLC with a high tumor mutation burden successfully treated with nivolumab. Anti-PD-1 antibodies might be a promising treatment strategy for patients with SMARCA4-deficient NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.